EZH2 and breast cancer: Subsequent studies have shown that HOTAIRM1 is capable of interacting with the Enhancer of zest homolog 2 (EZH2) of PRC2 and prevent the deposition of H3K27me3 marks at the HOXA1 promoter, thereby increasing HOXA1 levels in tamoxifen-resistant BC cells.